Lansoprazole

Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) [1][2].

Product Specifications

CAS Number

[103577-45-3]

Product Name Alternative

AG-1749

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Bacterial; Phospholipase; Proton Pump

Type

Reference compound

Related Pathways

Anti-infection; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/lansoprazole.html

Purity

99.92

Solubility

DMSO : ≥ 100 mg/mL|Ethanol : 10 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

Smiles

O=S(C1=NC2=CC=CC=C2N1)CC3=NC=CC(OCC(F)(F)F)=C3C

Molecular Formula

C16H14F3N3O2S

Molecular Weight

369.36

Precautions

H302, H315, H319, H335

References & Citations

[1]Kokufu, T., et al., Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol, 1995. 48 (5) : p. 391-5.|[2]Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35 (1) :1322-1330.|[3]Rupinder K Sodhi, et al. Defensive effect of lansoprazole in dementia of AD type in mice exposed to streptozotocin and cholesterol enriched diet. PLoS One. 2013 Jul 31;8 (7) :e70487.|[4]Jun Matsukawa, et al. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011 May 1;81 (9) :1145-51.|[5]Erdinc Naseri, et al. Proton pump inhibitors omeprazole and lansoprazole induce relaxation of isolated human arteries. Eur J Pharmacol. 2006 Feb 15;531 (1-3) :226-31.